𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia

✍ Scribed by Giulio Maria Pasinetti


Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
76 KB
Volume
65
Category
Article
ISSN
0360-4012

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Alzheimer's disease (AD) is the most common form of dementia, affecting as many as 4 million older persons and results from abnormal changes in the brain that most likely begin long before cognitive impairment and other clinical symptoms become apparent. Thus, efforts aimed at identifying methods of early detection and diagnosis for improving AD care might be the most appropriate strategy to initiate promising new treatments and/or prevention. We used cDNA microarray technology to investigate the sequence of changes in gene expression in brain that may take place during the transition from normal cognitive functioning through the early stages of impairment to frank AD. We examined the expression of approximately 7,000 genes in the brains of cases at the early stage of AD dementia using reference sample cases characterized by normal cognitive status. Genes that are differentially regulated in early AD cases were identified and were categorized into gene clusters based on similarities in biological functions. This analysis revealed that selected biological processes, including protein and amino acid metabolism, cytoskeleton integrity, and fatty acid metabolism, are involved in early phases of AD dementia. Most notable is the observation that selected genes involved in neurotransmitter release are differentially regulated in the brains of cases at high risk for dimentia. This evidence supports the feasibility and usefulness of cDNA microarray techniques to study sequential changes of distinctive gene‐expression patterns in the brain as a function of the progression of AD dementia. The study suggests new means to dissect and classify stages of AD dementia, or neuropathology, at the molecular level. J. Neurosci. Res. 65:471–476, 2001. Β© 2001 Wiley‐Liss, Inc.


πŸ“œ SIMILAR VOLUMES


The need for a consensus in the use of a
✍ Santiago Paulino Ramirez Diaz; Pedro Gil GregΓ³rio; Jose Manuel Ribera Casado; Em πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 64 KB πŸ‘ 1 views

## Aims To ensure that all Alzheimer centres across Europe are capable of using a similar method of data collection. Information about the patient assessment tools used by each participating centre was obtained and normal clinical practice in each EADC centre was documented by collecting data from

Criteria for onset critically influence
✍ Dr. John C. S. Breitner; Kathryn M. Magruder-Habib; D. C. Rao; G. P. Voglera πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 423 KB

The rare early-onset variant of Alzheimer's disease (AD) appears to be transmitted as an autosomal dominant genetic trait. More typical late-onset AD also shows familial aggregation, but possible genetic mechanisms are difficult to examine because the phenotypic expression of the putative AD genotyp

Multiple threshold model for the onset o
✍ Meyer, Joanne M.; Breitner, John C.S. πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 26 KB πŸ‘ 2 views

The three common alleles at the APOE locus influence the onset and lifetime risk of typical late-onset Alzheimer's disease (AD). Other loci may also alter risk of late-onset AD. One may assess the relative influence of APOE on the genetic contribution to AD by estimating the proportion of AD heritab

A change point model for estimating the
✍ Charles B. Hall; Richard B. Lipton; Martin Sliwinski; Walter F. Stewart πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 146 KB πŸ‘ 2 views

Dementia is characterized by accelerated cognitive decline before and after diagnosis as compared to normal ageing. Determining the time at which that rate of decline begins to accelerate in persons who will develop dementia is important both in describing the natural history of the disease process